When did Medpace Holdings, Inc. report Q4 2025 earnings?

Medpace Holdings, Inc. (MEDP) reported Q4 2025 earnings on February 9, 2026 after market close.

What were Medpace Holdings, Inc.'s Q4 2025 revenue and EPS?

Medpace Holdings, Inc. reported revenue of $708.5M and diluted EPS of $4.67 for Q4 2025.

Did Medpace Holdings, Inc. beat estimates in Q4 2025?

Revenue beat the consensus estimate of $689.3M by $19.1M. EPS beat the consensus estimate of $4.19 by $0.48.

How did Medpace Holdings, Inc.'s Q4 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 32.0% from $536.6M a year earlier and diluted EPS grew 27.2% from $3.67.

Where can I find Medpace Holdings, Inc.'s Q4 2025 SEC filings?

You can read the 8-K earnings release (0001668397-26-000004) and the 10-K periodic report (0001668397-26-000006) directly on SEC EDGAR. The filing index links above go to sec.gov.

Medpace Holdings, Inc. MEDP Q4 2025 Annual earnings

Reported February 9, 2026 · After market close

Revenue$708.5MBeat by $19.1M Diluted EPS$4.67Beat by $0.48

Revenue estimate$689.3M

EPS estimate$4.19

Next report

Jul 22, 2026 (in a month)

Revenue estimate$690.7M

EPS estimate$3.98

Financials

Q4 2025

Income statement

See full

Revenue$708.5M+32.0%

Operating income$153.3M+22.2%

Net income$135.1M+15.5%

EPS (diluted)$4.64+26.4%

Balance sheet

See full

Cash & equivalents$497.0M-25.8%

Total debt$136.9M-8.5%

Total equity$459.1M-44.4%

Total assets$2.0B-6.0%

Cash flow

See full

Operating cash flow$192.7M+1.0%

CapEx$4.5M-40.7%

Free cash flow$188.1M+2.8%

Valuation & ratios

Q4 2025

Valuation

See full

Market cap$15.82B+53.2%

Enterprise value$15.46B+57.7%

P/E35.1×+9.5×

P/S6.3×+1.4×

Profitability

See full

Operating margin21.1%0.0pp

Net margin17.8%-1.3pp

FCF margin26.9%-0.2pp

Returns & leverage

See full

Return on equity70.2%+11.8pp

Debt / equity0.3×+0.1×

Current ratio0.7×-0.2×

Segments

By product

See full

Oncology$249.8M+103%

Metabolic$195.9M+16.5%

Other$88.3M-14.5%

Cardiology$73.2M+48.7%

Central Nervous System$63.0M+8.1%

By segment

See full

Reportable Segment$708.5M+32.0%

Versus estimates

Revenue

Q1 2026$706.6MBeat by $9.0M

Q4 2025$708.5MBeat by $19.1M

Q3 2025$659.9MBeat by $18.9M Q2 2025$603.3MBeat by $64.5M Q1 2025$558.6MBeat by $32.2M Q4 2024$536.6MMiss by $3.2M

Diluted EPS

Q1 2026$4.28Beat by $0.54

Q4 2025$4.67Beat by $0.48

Q3 2025$3.86Beat by $0.33 Q2 2025$3.10Beat by $0.12 Q1 2025$3.67Beat by $0.61 Q4 2024$3.67Beat by $0.71

Ask the moment Medpace Holdings, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Medpace Holdings, Inc. report Q4 2025 earnings?: Medpace Holdings, Inc. (MEDP) reported Q4 2025 earnings on February 9, 2026 after market close.
What were Medpace Holdings, Inc.'s Q4 2025 revenue and EPS?: Medpace Holdings, Inc. reported revenue of $708.5M and diluted EPS of $4.67 for Q4 2025.
Did Medpace Holdings, Inc. beat estimates in Q4 2025?: Revenue beat the consensus estimate of $689.3M by $19.1M. EPS beat the consensus estimate of $4.19 by $0.48.
How did Medpace Holdings, Inc.'s Q4 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 32.0% from $536.6M a year earlier and diluted EPS grew 27.2% from $3.67.
Where can I find Medpace Holdings, Inc.'s Q4 2025 SEC filings?: You can read the 8-K earnings release (0001668397-26-000004) and the 10-K periodic report (0001668397-26-000006) directly on SEC EDGAR. The filing index links above go to sec.gov.